Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Bioinformatics dept. |
RCV000494924 | SCV000579471 | pathogenic | Stage 5 chronic kidney disease | 2016-11-02 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004730959 | SCV005337481 | likely pathogenic | GATA3-related disorder | 2024-04-05 | no assertion criteria provided | clinical testing | The GATA3 c.1051-1G>C variant is predicted to disrupt the AG splice acceptor site and interfere with normal splicing. This variant has not been reported in the literature or in a large population database indicating this variant is rare. Alternative variants at the same acceptor splice site have been observed in individuals with Hypoparathyroidism, Deafness, and Renal Dysplasia (HDR) Syndrome (1051-1G>T, Nesbit et al. 2004. PubMed ID: 14985365; c.1051-2A>G, Ali et al. 2007. PubMed ID: 17210674; c.1051-2A>G, Belge et al. 2017. PubMed ID: 27387476). Variants that disrupt the consensus splice acceptor site in GATA3 are expected to be pathogenic. This variant is interpreted as likely pathogenic. |